PMID- 28178490
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1525-0024 (Electronic)
IS  - 1525-0016 (Linking)
VI  - 16
IP  - 5
DP  - 2008 May
TI  - Administering Plasmid DNA Encoding Tumor Vessel-anchored IFN-alpha for Localizing 
      Gene Product Within or Into Tumors.
PG  - 901-906
LID - S1525-0016(16)31704-X [pii]
LID - 10.1038/mt.2008.40 [doi]
AB  - Tumor-targeted gene delivery has been intensively studied in the field of gene 
      therapy, but no attention has been given to targeting the therapeutic gene 
      products, which are transcribed and translated from the injected genes, into 
      tumors. Targeting immune stimulatory gene products into tumors is the key to 
      triggering tumor-specific CD8(+) T-cell responses and reducing systemic toxicity. 
      To target the gene products generated from the injected genes into tumors, genes 
      encoding the tumor-targeted fusion gene product were generated and administered 
      locally and systemically via electroporation. As anticipated, administration of a 
      therapeutic gene encoding IFN-alpha and the tumor vessel-targeted peptide CDGRC 
      fusion gene product minimizes the leakage of immunostimulatory cytokine from 
      tumors into the blood circulation, increases the infiltration of CD8(+) T cells 
      into tumors, induces a high magnitude of cytotoxic T-cell lysis (CTL) activity, 
      and reduces tumor vessel density. As a result, tumor growth was more 
      significantly inhibited by administering the IFN-alpha-CDGRC gene than by 
      administering the wild-type IFN-alpha gene. The same result was obtained with the 
      systemic administration of the tumor-targeted IFN-alpha gene. This gene product-based 
      tumor-targeted gene therapy approach could complement any other tumor-targeted 
      gene delivery method for improving tumor-targeting efficiency.
CI  - Copyright (c) 2008 The American Society of Gene Therapy. Published by Elsevier Inc. 
      All rights reserved.
FAU - Craig, Ryan
AU  - Craig R
AD  - Department of Comparative Biomedical Sciences, Louisiana State University, Baton 
      Rouge, Louisiana, USA.
FAU - Cutrera, Jeffry
AU  - Cutrera J
AD  - Department of Comparative Biomedical Sciences, Louisiana State University, Baton 
      Rouge, Louisiana, USA.
FAU - Zhu, Shiguo
AU  - Zhu S
AD  - Department of Comparative Biomedical Sciences, Louisiana State University, Baton 
      Rouge, Louisiana, USA.
FAU - Xia, Xueqing
AU  - Xia X
AD  - Department of Comparative Biomedical Sciences, Louisiana State University, Baton 
      Rouge, Louisiana, USA.
FAU - Lee, Yong-Hwan
AU  - Lee YH
AD  - Department of Biological Sciences, Louisiana State University, Baton Rouge, 
      Louisiana, USA.
FAU - Li, Shulin
AU  - Li S
AD  - Department of Comparative Biomedical Sciences, Louisiana State University, Baton 
      Rouge, Louisiana, USA. Electronic address: sli@vetmed.lsu.edu.
LA  - eng
PT  - Journal Article
DEP - 20161208
PL  - United States
TA  - Mol Ther
JT  - Molecular therapy : the journal of the American Society of Gene Therapy
JID - 100890581
EDAT- 2008/05/01 00:00
MHDA- 2008/05/01 00:01
CRDT- 2017/02/09 06:00
PHST- 2007/10/16 00:00 [received]
PHST- 2008/02/14 00:00 [accepted]
PHST- 2017/02/09 06:00 [entrez]
PHST- 2008/05/01 00:00 [pubmed]
PHST- 2008/05/01 00:01 [medline]
AID - S1525-0016(16)31704-X [pii]
AID - 10.1038/mt.2008.40 [doi]
PST - ppublish
SO  - Mol Ther. 2008 May;16(5):901-906. doi: 10.1038/mt.2008.40. Epub 2016 Dec 8.